Abstract

Objective To study the correlation between single nucleotide polymorphism of X-ray cross complementing group 1(XRCC1) and chemotherapy sensitivity of the advanced cervical cancer patients with TP chemotherapy regimens (taxol+ carboplatin). Methods The XRCC1 polymorphism at 399 site was detected in 97 patients with advanced cervical cancer patients, who recruited into our hospital from January 2010 to December 2011, by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). They were treated with TP chemotherapy and evaluated before and after three periods of chemotherapy, and then the correlation of the sensitivity of chemotherapy with polymorphisms was analyzed. The study protocol was approved by the Ethical Review Board of Investigation in Human Being of Affiliated Yancheng Hospital of Southeast University Medical College. Informed consent was obtained from all participates' parents. Results The total effective rate was 49.48%(48/97). The effective rates of chemotherapy were 38.24%(13/34) in patients with the XRCC1 codon 399 G/G, 47.37%(18/38) in 399 G/A, and 68.00%(17/25) in 399 A/A. There had significant difference of effective rates between 399 G/G and 399 A/A (P<0.05). Conclusions The genotype of XRCC1 Codon 399 may be used in prediction of chemotherapy efficacy for advanced cervical cancer. Key words: X-ray cross complementing group 1; polymorphism; chemotherapy; curative effect

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.